Literature DB >> 29179916

Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute.

Robert D Schouten1, Mirte Muller1, Cornedine J de Gooijer1, Paul Baas2, Michel van den Heuvel1.   

Abstract

Entities:  

Keywords:  Efficacy; Nivolumab; Non-small cell lung cancer; Real life; Safety

Mesh：

Substances：

Year:  2017        PMID： 29179916     DOI： 10.1016/j.lungcan.2017.11.012

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  11 in total

1.  Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer.

Authors:  Frederik A van Delft; Milou Schuurbiers; Mirte Muller; Sjaak A Burgers; Huub H van Rossum; Maarten J IJzerman; Hendrik Koffijberg; Michel M van den Heuvel
Journal:  Heliyon       Date:  2022-10-04

2.  Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care.

Authors:  Robert D Schouten; Lucie Egberink; Mirte Muller; Cornedine J De Gooijer; Erik van Werkhoven; Michel M van den Heuvel; Paul Baas
Journal:  Transl Lung Cancer Res       Date:  2020-10

3.  Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort.

Authors:  R A Juergens; C Mariano; J Jolivet; N Finn; J Rothenstein; M N Reaume; A Faghih; C Labbé; S Owen; F A Shepherd; J Villeneuve; F Romeyer; F Pettersson; C Butts
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

4.  Modeling Diagnostic Strategies to Manage Toxic Adverse Events following Cancer Immunotherapy.

Authors:  Frederik van Delft; Mirte Muller; Rom Langerak; Hendrik Koffijberg; Valesca Retèl; Daan van den Broek; Maarten IJzerman
Journal:  Med Decis Making       Date:  2021-04-05       Impact factor: 2.583

5.  Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Giorgia Guaitoli; Marcello Tiseo; Massimo Di Maio; Luc Friboulet; Francesco Facchinetti
Journal:  Transl Lung Cancer Res       Date:  2021-06

6.  Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients.

Authors:  Francesco Passiglia; Antonio Galvano; Marta Castiglia; Lorena Incorvaia; Valentina Calò; Angela Listì; Salvatore Mazzarisi; Alessandro Perez; Giuseppe Gallina; Sergio Rizzo; Hector Soto Parra; Viviana Bazan; Antonio Russo
Journal:  Ther Adv Med Oncol       Date:  2019-04-16       Impact factor: 8.168

7.  Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands.

Authors:  Christine M Cramer-van der Welle; Marjon V Verschueren; Merel Tonn; Bas J M Peters; Franz M N H Schramel; Olaf H Klungel; Harry J M Groen; Ewoudt M W van de Garde
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

8.  Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study.

Authors:  Fabrice Barlesi; Adrien Dixmier; Didier Debieuvre; Christophe Raspaud; Jean-Bernard Auliac; Nicolas Benoit; Pierre Bombaron; Denis Moro-Sibilot; Clarisse Audigier-Valette; Bernard Asselain; Thomas Egenod; Audrey Rabeau; Jérôme Fayette; Myriam Locatelli Sanchez; Jean-Luc Labourey; Virginie Westeel; Pauline Lamoureux; François-Emery Cotte; Victoria Allan; Melinda Daumont; Juliette Dumanoir; Dorothée Reynaud; Christophe Yannick Calvet; Nicolas Ozan; Maurice Pérol
Journal:  Oncoimmunology       Date:  2020-04-12       Impact factor: 8.110

9.  Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations.

Authors:  Francesco Passiglia; Federico Cappuzzo; Oscar Alabiso; Anna Cecilia Bettini; Paolo Bidoli; Rita Chiari; Carlotta Defferrari; Angelo Delmonte; Giovanna Finocchiaro; Guido Francini; Francesco Gelsomino; Diana Giannarelli; Monica Giordano; Alfonso Illiano; Lorenzo Livi; Olga Martelli; Clara Natoli; Gianfranco Puppo; Enrico Ricevuto; Elisa Roca; Daniele Turci; Domenico Galetta
Journal:  Br J Cancer       Date:  2018-10-31       Impact factor: 7.640

10.  Duration of nivolumab for pretreated, advanced non-small-cell lung cancer.

Authors:  Margaux Geier; Renaud Descourt; Romain Corre; Guillaume Léveiller; Régine Lamy; Éric Goarant; Jean-Louis Bizec; Cyril Bernier; Gilles Quéré; Karim Amrane; Elisabeth Gaye; François Lucia; Emilie Burte; Christos Chouaid; Gilles Robinet
Journal:  Cancer Med       Date:  2020-05-15       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.